Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Tagliabue, Elda"'
Autor:
Uva Valentina, Tagliabue Elda, Balsari Andrea, Cataldo Alessandra, Casalini Patrizia, Triulzi Tiziana, Sfondrini Lucia
Publikováno v:
Frontiers in Immunology. 4
Autor:
Balsari Andrea, Mariani Gabriella, Tagliabue Elda, Casalini Patrizia, Varchetta Stefania, Triulzi Tiziana, Bianchi Giulia, Sasso Marianna, Regondi Viola, Sfondrini Lucia
Publikováno v:
Frontiers in Immunology. 4
Autor:
De Cecco, Loris, Berardi, Martina, Sommariva, Michele, Cataldo, Alessandra, Canevari, Silvana, Mezzanzanica, Delia, Iorio, Marilena V., Tagliabue, Elda, Balsari, Andrea
Publikováno v:
PLoS ONE; Mar2013, Vol. 8 Issue 3, p1-10, 10p
Autor:
Narasimhadevara, Rupa, Pollak, Michael N., Foulkes, William D., Ménard, Sylvie, Casalini, Patrizia, Tagliabue, Elda, Pura, Serenella M., Balsari, Andrea, Veronesi, Umberto, Maisonneuve, Patrick, Rotmensz, Nicole, Decensi, Andrea, Viale, Giuseppe, Boyle, Peter, Tokumaru, Yutaka, Sun, Dong-Il, Nomoto, Shuji, Yamashita, Keishi, Sidransky, David
Publikováno v:
JNCI: Journal of the National Cancer Institute; 6/18/2003, Vol. 95 Issue 12, p917, 4p, 2 Charts
Autor:
Michael F. Press, Dennis J. Slamon, Joan S. Brugge, Sara A. Hurvitz, Jason J. Zoeller, Judy Dering, Laura M. Selfors
Publikováno v:
PLoS ONE
PloS one, vol 16, iss 5
PLoS ONE, Vol 16, Iss 5, p e0251163 (2021)
PloS one, vol 16, iss 5
PLoS ONE, Vol 16, Iss 5, p e0251163 (2021)
Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gen
Autor:
Rossella Canese, Elda Tagliabue, Patrizia Nanni, Egidio Iorio, Daniele Morelli, Massimo Di Nicola, Simona Faraci, Patrizia Casalini, Lorenzo Castagnoli, Matteo Dugo, Claudio Vernieri, Ada Koschorke, Serenella M. Pupa
Publikováno v:
Journal of Cellular Physiology
Despite different molecular tumor profiles indicate that human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) levels mirror HER2 addiction and trastuzumab benefit in HER2-positive breast cancer (BC), the identification of noninvasive
Autor:
Viola Regondi, Stefania Arioli, Elda Tagliabue, Arianna Bonizzi, Francesca Bianchi, Beatrice Belmonte, Alessia Bertolotti, Claudio Tripodo, Andrea Balsari, Elena Fasano, Tiziana Triulzi, Loris De Cecco, Fabio Corsi, Martina Di Modica, Simone Guglielmetti, Giorgio Gargari, Laura Villani
Publikováno v:
Cancer research. 81(8)
Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclin
Autor:
Laura Botti, Maria Teresa Majorini, Claudio Tripodo, Alice Rigoni, Mario P. Colombo, Valeria Cancila, Claudia Chiodoni, Loris De Cecco, Daniele Lecis, Enrico Fontanella, Elena Jachetti, Matteo Dugo, Tiziana Triulzi, Elda Tagliabue
Tumor growth and development is determined by both cancer cell–autonomous and microenvironmental mechanisms, including the contribution of infiltrating immune cells. Because the role of mast cells (MC) in this process is poorly characterized and ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5961be16be787af28bb8b55bc9f2933
http://hdl.handle.net/10447/414607
http://hdl.handle.net/10447/414607
Autor:
Maria Rosa Cappelletti, Elda Tagliabue, Loris De Cecco, Martina Di Modica, Tiziana Triulzi, Daniele Generali, Serena Di Cosimo, Biagio Paolini, Pier Luigi Lollini, Viola Regondi, Lucia Sfondrini
Publikováno v:
British Journal of Cancer
Background: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of tr
Autor:
A. Berruti, D. Generali, M. Kaufmann, L. Puztai, G. Curigliano, M. Aglietta, L. Gianni, W. R. Miller, M. Untch, C. Sotiriou, M. Daidone, P. Conte, D. Kennedy, G. Damia, P. Petronini, S. Di Cosimo, P. Bruzzi, M. Dowsett, C. Desmedt, R. E. Mansel, L. Olivetti, C. Tondini, A. Sapino, P. Fenaroli, G. Tortora, H. Thorne, F. Bertolini, F. Ferrozzi, M. Danova, E. Tagliabue, E. de Azambuja, A. Makris, M. Tampellini, G. Dontu, L. Van't Veer, A. L. Harris, S. B. Fox, L. Dogliotti, A. Bottini
A panel of international breast cancer experts formulated a declaration of consensus regarding many key issues in the use of primary systemic therapy (PST) either in clinical routine or research practice. The attainment of pathological complete respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0a87e484de7048530157d938346d7e5
http://hdl.handle.net/11379/469038
http://hdl.handle.net/11379/469038